{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:41:54Z","timestamp":1789753314869,"version":"4.0.1"},"reference-count":64,"publisher":"SAGE Publications","issue":"5-6","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>\n                    The use of human adenoviruses (hAds) as oncolytic agents has demonstrated considerable potential. However, their efficacy in clinical studies is generally moderate and often varies between patients. This may, in part, be attributable to variable pre-existing neutralizing immunity in patients, which can impact the antitumor efficacy and lead to response heterogeneity. Our aim was to isolate new Ads for the development of oncolytic vectors with low prevalence of neutralizing immunity in the human population. To this end, we isolated a collection of new nonhuman primate (nhp) Ads from stool samples of four great ape species held captive. We elected 12 isolates comprising the broadest genetic variability for further characterization. For three new nhpAds, all classified as the human adenovirus B (HAdV-B) species, no neutralizing activity could be detected when exposed to a preparation of immunoglobulins isolated from a pool of &gt;1,000 donors as a surrogate of population immunity. In addition, the nhpAds of the HAdV-B species showed enhanced oncolytic potency compared to nhpAds of the HAdV-C species as well as to human adenovirus type 5 (HAdV-C5)\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    when tested in a panel of 29 human cancer cell lines. Next-generation sequencing of the viral genomes revealed higher sequence similarity between hAds and nhpAds of HAdV-B compared to HAdV-C, which might underlie the differences in oncolytic ability. As a proof-of-concept, the Rb-binding domain of the E1A protein of the gorilla-derived HAdV-B nhpAd-lumc007 was deleted, thereby creating a new oncolytic derivative, which demonstrated increased oncolytic potential compared to HAdV-C5. Collectively, our data demonstrate that nhpAds of the HAdV-B species can serve as an alternative for the development of potent oncolytic Ad vectors with limited pre-existing neutralizing immunity in humans.\n                  <\/jats:p>","DOI":"10.1089\/hum.2021.216","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T00:10:05Z","timestamp":1638576605000},"page":"275-289","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates"],"prefix":"10.1177","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1844-9247","authenticated-orcid":false,"given":"Selas T.F.","family":"Bots","sequence":"first","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve J.","family":"Cramer","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-3182","authenticated-orcid":false,"given":"Diana J.M.","family":"van den Wollenberg","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Hornsveld","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine L.M.","family":"Lamfers","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Tumor Center, Erasmus Medical Center, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabri","family":"van der Pluijm","sequence":"additional","affiliation":[{"name":"Department of Urology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.","family":"Hoeben","sequence":"additional","affiliation":[{"name":"Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-021-01111-8"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.348523.121"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2236-3"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0644-7"},{"key":"e_1_3_6_6_2","first-page":"1","article-title":"Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy","volume":"2","author":"Belcaid Z","year":"2020","unstructured":"Belcaid Z, , Berrevoets C, , Choi J, et al. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Neuroncol Adv, 2020; 2:1\u201312.","journal-title":"Neuroncol Adv"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2016.11.003"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8219"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00354-11"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00491-11"},{"key":"e_1_3_6_11_2","unstructured":"King AMQ Lefkowitz E eds. Ninth Report of the International Committee on Taxonomy of Viruses. Virus Taxonomy. USA: Elsevier Inc. 2012."},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.15.8263-8271.2003"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.289"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.67"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00243-x"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/v8030078"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00740-12"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.075"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31604-4"},{"key":"e_1_3_6_20_2","first-page":"1","article-title":"Non-human primate-derived adenoviruses for future use as oncolytic agents?","volume":"21","author":"Hoeben RC","year":"2020","unstructured":"Bots STF & Hoeben RC. Non-human primate-derived adenoviruses for future use as oncolytic agents?. Int J Mol Sci, 2020; 21:1\u201320.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000250"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1996.7.2-215"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-4827(90)90012-Y"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not116"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.05.005"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070168"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700329"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000503"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.18860-0"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2836(83)80284-8"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(99)00033-6"},{"key":"e_1_3_6_33_2","first-page":"115","article-title":"The polypeptides of adenovirus","volume":"125","author":"Maizel JV","year":"1968","unstructured":"Maizel JV, , White JDO, , Scharff MD. The polypeptides of adenovirus. Electrophoresis, 1968; 125:115\u2013125.","journal-title":"Electrophoresis"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00449-13"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep27459"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.12.014"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.9.4426-4433.2005"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00011-14"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.612"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.74"},{"key":"e_1_3_6_41_2","author":"Wang H","unstructured":"Wang H, , Cai Z, , Yang F, et al. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F\/RGD on bladder cancer. Urology 2014;83:508.e13\u2013e508.e19.","journal-title":"Urology"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6822(02)00085-5"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/08830180490265556"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep01812"},{"key":"e_1_3_6_45_2","doi-asserted-by":"crossref","unstructured":"Hatakeyama M Weinberg RA eds. The Role of RB in Cell Cycle Control. Boston MA: Progress in Cell Cycle Research 1995.","DOI":"10.1007\/978-1-4615-1809-9_2"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203251"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.06254-11"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.3.2388-2397.1998"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15845"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.9.3643-3650.1989"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.3.11.1699"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.05.018"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2004.08.007"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21186828"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2010.79"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002409"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.015"},{"key":"e_1_3_6_58_2","first-page":"120","article-title":"A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency","volume":"7","author":"Suzuki K","year":"2001","unstructured":"Suzuki K, , Fueyo J, , Krasnykh V, et al. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res, 2001; 7:120\u2013126.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-639"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00265-20"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1681"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00360-2"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.3390\/v13071271"},{"key":"e_1_3_6_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001486"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2020.02.001"}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2021.216","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2021.216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:56:26Z","timestamp":1777449386000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2021.216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":64,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1089\/hum.2021.216"],"URL":"https:\/\/doi.org\/10.1089\/hum.2021.216","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}